BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 10452969)

  • 1. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
    Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
    J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
    Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
    J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.
    Carnaud C; Lee D; Donnars O; Park SH; Beavis A; Koezuka Y; Bendelac A
    J Immunol; 1999 Nov; 163(9):4647-50. PubMed ID: 10528160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
    Tomura M; Yu WG; Ahn HJ; Yamashita M; Yang YF; Ono S; Hamaoka T; Kawano T; Taniguchi M; Koezuka Y; Fujiwara H
    J Immunol; 1999 Jul; 163(1):93-101. PubMed ID: 10384104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells.
    Kitamura H; Ohta A; Sekimoto M; Sato M; Iwakabe K; Nakui M; Yahata T; Meng H; Koda T; Nishimura S; Kawano T; Taniguchi M; Nishimura T
    Cell Immunol; 2000 Jan; 199(1):37-42. PubMed ID: 10675273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of both IL-27 and IFN-gamma after the treatment with a ligand for invariant NK T cells is responsible for the suppression of Th2 response and allergic inflammation in a mouse experimental asthma model.
    Fujita H; Teng A; Nozawa R; Takamoto-Matsui Y; Katagiri-Matsumura H; Ikezawa Z; Ishii Y
    J Immunol; 2009 Jul; 183(1):254-60. PubMed ID: 19542437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
    Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
    Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus.
    Exley MA; Bigley NJ; Cheng O; Tahir SM; Smiley ST; Carter QL; Stills HF; Grusby MJ; Koezuka Y; Taniguchi M; Balk SP
    J Leukoc Biol; 2001 May; 69(5):713-8. PubMed ID: 11358978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
    Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
    Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
    Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
    Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system.
    Youn HJ; Ko SY; Lee KA; Ko HJ; Lee YS; Fujihashi K; Boyaka PN; Kim SH; Horimoto T; Kweon MN; Kang CY
    Vaccine; 2007 Jul; 25(28):5189-98. PubMed ID: 17548137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen-stimulated cytokine and antibody responses.
    Wang M; Ellison CA; Gartner JG; HayGlass KT
    J Immunol; 1998 Feb; 160(3):1098-105. PubMed ID: 9570522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice.
    Yoshimoto T; Min B; Sugimoto T; Hayashi N; Ishikawa Y; Sasaki Y; Hata H; Takeda K; Okumura K; Van Kaer L; Paul WE; Nakanishi K
    J Exp Med; 2003 Apr; 197(8):997-1005. PubMed ID: 12695491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.
    Brossay L; Naidenko O; Burdin N; Matsuda J; Sakai T; Kronenberg M
    J Immunol; 1998 Nov; 161(10):5124-8. PubMed ID: 9820479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway.
    Miellot A; Zhu R; Diem S; Boissier MC; Herbelin A; Bessis N
    Eur J Immunol; 2005 Dec; 35(12):3704-13. PubMed ID: 16304639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.